Clinical Trials

Microbiotica has dosed the first subject in the Phase Ib MELODY-1 clinical trial of MB097, a precision microbiome co-therapy targeting advanced melanoma.

During a Case-Based Roundtable® event, Ahmad Tarhini, MD, PhD, discussed the indirect comparison of ipilimumab plus nivolumab and nivolumab/relatlimab in advanced melanoma in the second article of a 2-part series.

Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF V600–positive melanoma.

Ahmad Tarhini, MD, PhD: This was a first-line patient population with untreated metastatic melanoma who were randomly assigned 1:1 to a fixed-dose combination of nivolumab at 480 mg and relatlimab at 160 mg [Opdualag]. This was a fixed-dose single infusion on the study given over 60 minutes.